Ihr Broker

  • DAX 0,70
  • EUR/USD 0,50
  • GOLD 0,30

Nur Spreads

Keine Kommission

Jetzt registrieren

CFDs sind komplexe Instrumente und umfassen aufgrund der Hebelfinanzierung ein hohes Risiko, schnell Geld zu verlieren.

Medacta Group SA, CH0468525222

Medacta Group SA, CH0468525222

13.07.2021 - 07:03:55

EQS-Adhoc: Medacta Group SA announces the final settlement in the Microport case

Press Release - Ad-hoc announcement pursuant to Art. 53 LR

Medacta Group SA announces the final settlement in the Microport case

CASTEL SAN PIETRO, 13 July 2021 - With reference to its media release of February 19, 2020 and note 6.24 of its 2020 Financial Statements, Medacta Group SA ("Medacta", SIX:MOVE) announces today that its subsidiary Medacta USA, Inc. and Medacta International SA have entered into an agreement with MicroPort Orthopedics, a subsidiary of MicroPort Scientific Corporation, to settle a suit accusing of patent infringement and tortious interference with contract. The settlement also resolves MicroPort's claims against its former distributor, Advanced Surgical Devices, Inc. Accordingly, all matters referred to as "the Microport Matter" in note 6.24 of the 2020 Financial Statements are fully, finally and completely settled.

According to the agreement, Medacta USA will pay to MicroPort Inc. the sum of $7 million by five days after the signature of the agreement, the sum of $5 million over a term of seven years. In addition, the settlement agreement contemplates the contribution by Medacta of marketing activities in a low single digit amount over a period of four years.

ContactMedacta International SA Gianna La Rana, Head of Investor Relations Phone: +41 91 696 14 95 investor.relations@medacta.ch

About Medacta Medacta is an international company specializing in the design, production, and distribution of innovative orthopaedic products, as well as in the development of accompanying surgical techniques. Established in 1999 in Switzerland, Medacta is active in joint replacement, spine surgery, and sports medicine. Medacta is committed to improving the care and well-being of patients and maintains a strong focus on healthcare sustainability. Medacta's innovation, forged by close collaboration with surgeon leaders globally, began with minimally invasive surgical techniques and has evolved into personalized solutions for every patient. Through the M.O.R.E. Institute, Medacta supports surgeons with a comprehensive and tailored program dedicated to the advancement of medical education. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 40 countries.

End of ad hoc announcement Language: English Company: Medacta Group SA Strada Regina 6874 Castel San Pietro

Switzerland Phone: +41 91 696 6060 E-mail: info@medacta.ch,investor.relations@medacta.ch Internet: www.medacta.com ISIN: CH0468525222 Listed: SIX Swiss Exchange EQS News ID: 1217998 ? End of Announcement EQS Group News Service

1217998??13-Jul-2021?CET/CEST

@ dgap.de